ArticleSkin health and disease2026
Long-term postmarketing safety of psoriasis treatments on autoimmune disease risk: a 15-year nationwide cohort study in Denmark.
Article in Skin health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psoriasis is a chronic immune-mediated skin disease, reported to affect approximately 2-3% of the global population, with prevalence in Denmark estimated at around 5%. Objectives: To assess the long-term safety of interleukin (IL) inhibitors in relation ot secondary autoimmune diseases. Methods: Among patients with psoriasis diagnosed between 1994 and 2023, a total of 36 155 were followed during their treatment exposure (2009-2023) using data from the Danish National Patient and Prescription Registries. Exposure groups included IL inhibitors, tumour necrosis factor (TNF)-α inhibitors, and nonbiologic treatments. Different analytical approaches used in the analyses included intention-to-treat (ITT), on-treatment (OT) and continuous index treatment estimands. Hazard ratios (HRs) were calculated using Cox regression models, and supplementary analyses examined prior autoimmune disease and psoriatic arthritis (PsA) status. Results: IL inhibitors were consistently found to be associated with a lower risk of developing secondary autoimmune diseases. Based on the ITT estimand, TNF-α inhibitors were associated with a 54% increased risk [HR 1.54, 95% confidence interval (CI) 1.06-2.24] of selected autoimmune diseases. Based on the OT estimand, nonbiologic treatments were associated with an elevated risk (HR 1.57, 95% CI 1.01-2.42). Supplementary analyses including patient history of prior autoimmune disease and PsA status suggested effects in the same directions. Conclusions: The present national population-based cohort study, which included all Danish patients diagnosed with psoriasis in hospital settings between 2009 and 2023, found that IL inhibitors were not associated with a higher risk of secondary autoimmune diseases than TNF-α inhibitors and nonbiologic treatments. These findings were observed regardless of patients' pre-existing autoimmune comorbidities. Thus, IL inhibitors were not associated with a higher risk of developing subsequent autoimmune diseases, even among patients with existing autoimmune conditions. These findings may help inform clinicians' treatment decisions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.